Triple negative breast cancer patients who are unlikely to respond to immunotherapies are identified by genetic testing.

Published Date: 20 Mar 2024

A new genetic test that predicts the response of patients with triple negative early-stage breast cancer to immunotherapy medications has been developed by researchers. Those who are not likely to benefit from these medications are affected by this.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot